Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 09, 2021

SELL
$181.39 - $202.99 $2.85 Million - $3.18 Million
-15,686 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $245,424 - $289,419
-1,309 Reduced 7.7%
15,686 $3.16 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $151,952 - $177,121
-734 Reduced 4.14%
16,995 $3.65 Million
Q4 2020

Feb 08, 2021

BUY
$207.01 - $276.09 $246,548 - $328,823
1,191 Added 7.2%
17,729 $4.19 Million
Q3 2020

Nov 09, 2020

SELL
$255.65 - $303.1 $7.14 Million - $8.47 Million
-27,938 Reduced 62.82%
16,538 $4.5 Million
Q2 2020

Aug 10, 2020

SELL
$225.48 - $295.8 $4.51 Million - $5.91 Million
-19,983 Reduced 31.0%
44,476 $12.9 Million
Q1 2020

May 14, 2020

SELL
$199.77 - $247.81 $785,295 - $974,141
-3,931 Reduced 5.75%
64,459 $15.3 Million
Q4 2019

Feb 12, 2020

SELL
$166.71 - $223.91 $136,035 - $182,710
-816 Reduced 1.18%
68,390 $15 Million
Q3 2019

Nov 08, 2019

SELL
$166.23 - $187.09 $462,451 - $520,484
-2,782 Reduced 3.86%
69,206 $11.7 Million
Q2 2019

Jul 25, 2019

BUY
$164.61 - $190.37 $11.8 Million - $13.7 Million
71,988 New
71,988 $13.2 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Rothschild & CO Asset Management Us Inc. Portfolio

Follow Rothschild & CO Asset Management Us Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

News

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.